Basic Information
| LncRNA/CircRNA Name | BCLIN25 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Herceptin,Paclitaxel | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay, Western blot analysis |
| Sample | Breast cancer and adjacent noncancerous tissues,mammary cells(MCF-10A), breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, Hs-578T, MCF-7, UACC-812,SKBR3,T47D, and BT-549) |
| Expression Pattern | up-regulated |
| Function Description | BCLIN25 was found to contribute to tumorigenesis in vitro and in vivo. Mechanistically, BCLIN25 was shown to increase the expression of ERBB2 by enhancing promoter CpG methylation of miR-125b, leading to miR-125b downregulation. |
| Pubmed ID | 31801944 |
| Year | 2019 |
| Title | The MS-lincRNA Landscape Reveals a Novel lincRNA BCLIN25 That Contributes to Tumorigenesis by Upregulating ERBB2 Expression via Epigenetic Modification and RNA-RNA Interactions in Breast Cancer |
External Links
| Links for BCLIN25 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |